https://www.openbell.ai/ 2026-10-13T11:45:12.711Z hourly 1.0 https://www.openbell.ai/support 2026-10-13T11:45:12.711Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-13T11:45:12.711Z monthly 0.5 https://www.openbell.ai/terms 2026-10-13T11:45:12.711Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-13T11:45:12.711Z hourly 0.8 https://www.openbell.ai/news/SCNX:1791891907635 2026-10-13T11:45:07.635Z daily 0.9 https://cdn.brandfetch.io/SCNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability Scienture Holdings Inc. reported preliminary third-quarter revenue of approximately $1.22 million, a 256% increase from $344,000 in the previous quarter, driven by rising sales of its blood pressure medication Arbli and initial shipments of the newly launched Rezenopy. The company aims for profitability by 2027, leveraging its expanding product portfolio and high gross margins. Scienture's shares rose 2.08% to $3.99 during premarket trading. https://www.openbell.ai/news/GOOG:1791891673682 2026-10-13T11:41:13.682Z daily 0.9 https://cdn.brandfetch.io/GOOG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported October 12, Anthropic Says AI Models May Be Capable Of Self-Replicating Without Access To A Data Center On October 12, Anthropic announced that its AI models may have the capability to self-replicate without needing access to a data center. This development could have significant implications for the AI industry and technology sector. The news may influence market perceptions, particularly regarding companies like Google (GOOG), which are heavily invested in AI technologies. https://www.openbell.ai/news/ZBH:1791891556369 2026-10-13T11:39:16.369Z daily 0.9 https://cdn.brandfetch.io/ZBH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zimmer Biomet Expands Its Distribution, Supply Deal With THINK Surgical To Continue Distribution Of THINK's Wireless TMINI Miniature Robotic System Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement with THINK Surgical, Inc. This agreement allows Zimmer Biomet to continue distributing an exclusive version of THINK's wireless TMINI Miniature Robotic System, which is compatible with Zimmer Biomet's Persona Knee System, following a successful initial partnership. https://www.openbell.ai/news/BWAY:1791891487462 2026-10-13T11:38:07.462Z daily 0.9 https://cdn.brandfetch.io/BWAY/w/400/h/400?c=1idopYfmtR7ZKg8QMud BrainsWay Says Over 70M U.S. Covered Lives Now Have Access To Policies Covering SWIFT Accelerated Depression Treatment openbell Financial News https://www.openbell.ai/news/DGXX:1791891400651 2026-10-13T11:36:40.651Z daily 0.9 https://cdn.brandfetch.io/DGXX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Digi Power X Receives Commitment Letter For $200M In Debt Financing To Develop Its 40 MW AI Data Center In Columbiana, Alabama Digi Power X has secured a commitment letter for $200 million in debt financing, arranged by Goldman Sachs, to support the development of its 40 MW AI data center in Columbiana, Alabama. The company currently holds approximately $135 million in cash and has invested $153 million in capital expenditures in 2026. Construction of the Alabama campus is on schedule, with Phase 1 expected to complete by December 2026. Additionally, Digi Power X is planning to repurpose its New York sites into AI token factories and has acquired a facility in Silicon Valley to enhance its AI capabilities. https://www.openbell.ai/news/SA:1791891287126 2026-10-13T11:34:47.126Z daily 0.9 https://cdn.brandfetch.io/SA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Seabridge Gold To Acquire 100% Interest In Properties And Data Of The Slaughterhouse Project In Southern Wyoming From Orogen Royalties For $300K And Milestone Payments Of Up To $2.55M Seabridge Gold has agreed to acquire a 100% interest in the Slaughterhouse Project in Southern Wyoming from Orogen Royalties for $300,000, along with potential milestone payments of up to $2.55 million. The acquisition includes 163 US mining claims and various geological data. Orogen will retain a 2.5% net smelter return royalty on the existing claims and a 0.5% to 1% royalty in a broader area of mutual interest. The transaction is subject to customary closing conditions. https://www.openbell.ai/news/ARAI:1791891263638 2026-10-13T11:34:23.638Z daily 0.9 https://cdn.brandfetch.io/ARAI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arrive AI Collaborates With Rivo To Integrate Arrive Points Into Rivo's Autonomous Delivery Ecosystem Arrive AI (NASDAQ: ARAI) has announced a collaboration with Rivo to integrate its Arrive Points™ into Rivo's autonomous delivery ecosystem. The partnership will focus on secure autonomous delivery solutions, starting with a proof-of-concept program at a golf property in Palm Beach, Florida, aimed at delivering food, beverages, and merchandise. This initiative highlights the companies' efforts to enhance logistics in the luxury hospitality sector. https://www.openbell.ai/news/ACI:1791891157327 2026-10-13T11:32:37.327Z daily 0.9 https://cdn.brandfetch.io/ACI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Albertons Rolling Out Business Review To Speed Up Performance Enhancements; To Offer Refreshed Financial Framework, Both Short & Long-term, Alongside Its Comprehensive Turnaround Plan By Q4 Albertsons Companies, Inc. (NYSE: ACI) has announced a business review aimed at accelerating performance enhancements and will introduce a refreshed financial framework, both short and long-term, as part of its comprehensive turnaround plan by Q4 2026. The company reported its second-quarter results for fiscal 2026, which ended on September 12, 2026. https://www.openbell.ai/news/ZTG:1791891131155 2026-10-13T11:32:11.155Z daily 0.9 https://cdn.brandfetch.io/ZTG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zenta Group Announces Management-Endorsed Strategic Re-Alignment To Refocus Its Business Operations On AI And Data Solutions Zenta Group Company Limited (NASDAQ: ZTG) has announced a strategic re-alignment to focus its business operations on AI and data solutions, following a management-endorsed proposal approved by the board of directors. This decision is supported by a share purchase agreement to acquire 100% of ZentoAI Intelligent Technology Company Limited, enhancing the company's capabilities in the AI sector. The move comes in response to uncertain property market conditions in the Guangdong–Hong Kong–Macao Greater Bay Area, while demand for AI and data solutions is expected to grow across Asia. https://www.openbell.ai/news/ACI:1791891066452 2026-10-13T11:31:06.452Z daily 0.9 https://cdn.brandfetch.io/ACI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Albertsons Companies Q2 Adj. EPS $0.36 Beats $0.33 Estimate, Sales $18.895B Beat $18.867B Estimate Albertsons Companies (NYSE: ACI) reported Q2 adjusted earnings per share of $0.36, exceeding the analyst estimate of $0.33 by 9.09%, though this reflects an 18.18% decrease from $0.44 per share in the same quarter last year. The company's quarterly sales reached $18.895 billion, surpassing expectations of $18.867 billion by 0.15%, but showing a slight decline of 0.11% compared to $18.915 billion in the previous year. https://www.openbell.ai/news/NFLX:1791891006075 2026-10-13T11:30:06.075Z daily 0.9 https://cdn.brandfetch.io/NFLX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Netflix Secures Exclusive Rights In Spain And Andorra To 2030 FIFA World Cup Netflix has secured exclusive broadcasting rights for the 2030 FIFA World Cup in Spain and Andorra. This strategic move enhances Netflix's sports content offerings and aims to attract more subscribers in these markets. The deal is expected to bolster the company's position in the competitive streaming landscape. https://www.openbell.ai/news/NFLX:1791890939002 2026-10-13T11:28:59.002Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Netflix-Logo-On-A-Building-Exterior-With.jpg?width=250&height=187 Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’ On CNBC's 'Halftime Report Final Trades', Stephen Weiss recommended Netflix (NASDAQ:NFLX), which has an Overweight rating from Morgan Stanley, although the price target was lowered from $83 to $80. Jim Lebenthal endorsed AbbVie (NYSE:ABBV), noting strong momentum following the FDA's granting of two Breakthrough Therapy Designations for a new treatment. Jenny Van Leeuwen Harrington highlighted DocuSign (NASDAQ:DOCU), which reported second-quarter revenue of $875.75 million, exceeding estimates, and has a free cash flow yield of nearly 10%. On October 9, Netflix shares rose 0.4% to $70.61, AbbVie increased 1.7% to $281.12, while DocuSign's shares fell 0.2% to $70.97. https://www.openbell.ai/news/GS:1791890843794 2026-10-13T11:27:23.794Z daily 0.9 https://cdn.brandfetch.io/GS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Gr Q3 EPS $17.01 Beats $13.08 Estimate, Sales $18.679B Beat $16.705B Estimate Goldman Sachs Group (NYSE: GS) reported Q3 earnings of $17.01 per share, surpassing the analyst estimate of $13.08 by 30.05%, and marking a 38.86% increase from $12.25 per share in the same quarter last year. The company's quarterly sales reached $18.679 billion, exceeding the $16.705 billion estimate by 11.82%, and reflecting a 23.05% increase from $15.180 billion in the previous year. https://www.openbell.ai/news/BKYI:1791890749217 2026-10-13T11:25:49.217Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Volatility.jpg?width=250&height=187 Why Is BIO-key International Stock Surging Tuesday? BIO-key International Inc. (NASDAQ: BKYI) saw its stock surge over 130% in premarket trading, reaching $3.82, after announcing a new government agency customer in the Middle East for its multi-factor authentication platform. The company did not disclose the financial terms of the agreement, which is expected to enhance its presence in the region. Trading volume reached 31.13 million shares, significantly higher than its 100-day average of 2.73 million shares, with short interest at 71.29% of the public float, indicating potential for volatility. https://www.openbell.ai/news/BKYI:1791890685733 2026-10-13T11:24:45.733Z daily 0.9 https://cdn.brandfetch.io/BKYI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is BIO-key International Stock Surging Tuesday? BIO-key International Inc. (NASDAQ: BKYI) saw its stock surge over 130% in premarket trading, reaching $3.82, after announcing a new government agency customer in the Middle East for its multi-factor authentication platform. The company did not disclose financial terms of the agreement, but the contract is expected to enhance its presence in the region, joining a portfolio that includes major defense organizations. Trading volume spiked to 31.13 million shares, significantly above the 100-day average, with short interest at 71.29% of the public float, indicating potential for volatility. https://www.openbell.ai/news/META:1791890641858 2026-10-13T11:24:01.858Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/New-York--Usa---14-December-2024-Meta-Pl.jpg?width=250&height=187 Dan Ives Says Meta's 'Frontier Model' and 3.6 Billion Users Make It a ‘Core Name’ to Own as It Competes With Anthropic and OpenAI Dan Ives, a technology analyst, has reaffirmed a strong investment outlook on Meta Platforms Inc. (NASDAQ: META), highlighting its 3.6 billion daily users and advanced AI capabilities as key competitive advantages. Ives noted that Meta is well-positioned in the ongoing AI arms race, actively pursuing market share against leaders like Anthropic and OpenAI. Currently, Meta's stock is up 12.55% year-to-date, despite a slight dip of 1.34% to $733 in premarket trading. https://www.openbell.ai/news/XTIA:1791890639146 2026-10-13T11:23:59.146Z daily 0.9 https://cdn.brandfetch.io/XTIA/w/400/h/400?c=1idopYfmtR7ZKg8QMud XTI Aerospace Withdraws Previously Issued 2026 Financial Guidance And Expects To Provide Comprehensive Update At Later Date XTI Aerospace has withdrawn its previously issued financial guidance for 2026 and plans to provide a comprehensive update at a later date. The company has not specified the reasons for this withdrawal. The stock ticker for XTI Aerospace is XTIA. https://www.openbell.ai/news/BHST:1791890608906 2026-10-13T11:23:28.906Z daily 0.9 https://cdn.brandfetch.io/BHST/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization BioHarvest Sciences has announced that its proprietary Olive Cell Composition has achieved commercial readiness, completing development and commercial-scale manufacturing at its GMP facility. The asset, developed through Botanical Synthesis™, has passed the self-affirmed GRAS process and is now available for licensing and commercialization. The olive-derived Verbascoside composition shows promising preclinical activity in liver steatosis and fibrosis models, indicating potential applications across various health and wellness categories. https://www.openbell.ai/news/OKLO:1791890492034 2026-10-13T11:21:32.034Z daily 0.9 https://cdn.brandfetch.io/OKLO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oklo To Advance Groves Isotope Production Facility As Part Of US DOE’s National Reactor Innovation Center Nuclear Energy Launch Pad Initiative Oklo Inc. has been selected by the U.S. Department of Energy's National Reactor Innovation Center to advance its Groves isotope production facility, known as Groves 2 Forge, as part of the Nuclear Energy Launch Pad initiative. The facility will initially focus on producing lutetium-177, an isotope used in cancer treatments, and aims to transition to commercial-scale production with the necessary U.S. Nuclear Regulatory Commission licenses. This initiative builds on the experience gained from Oklo's Groves Isotope Test Reactor in Texas. https://www.openbell.ai/news/GE:1791890466702 2026-10-13T11:21:06.702Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Beavercreek---May-31--2024-Ge-Aerospace-.jpg?width=250&height=187 GE Aerospace Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call GE Aerospace is set to release its third-quarter earnings report on October 20, with analysts expecting earnings of $1.99 per share and revenue of $12.84 billion, compared to $1.66 per share and $11.3 billion in the same quarter last year. The company recently entered an agreement with Military Aviation Works No. 1 to provide maintenance for T700/CT7 engines in Poland. GE Aerospace shares closed at $308.64, reflecting a 0.1% increase. https://www.openbell.ai/news/MGM:1791890351503 2026-10-13T11:19:11.503Z daily 0.9 https://cdn.brandfetch.io/MGM/w/400/h/400?c=1idopYfmtR7ZKg8QMud MGM Resorts International Unit BetMGM Reports Q3 Net Sales Of $710M, Up 7% YoY BetMGM, a unit of MGM Resorts International, reported Q3 net sales of $710 million, reflecting a 7% year-over-year increase. The iGaming segment generated $483 million in net revenue, up 6% YoY, while online sports revenue reached $216 million, a 7% increase. Adjusted EBITDA for the quarter was $86 million, marking a significant 112% rise YoY. BetMGM also reaffirmed its FY 2026 guidance, targeting net revenue between $2.9 billion and $3.1 billion and adjusted EBITDA of $300 million to $350 million. https://www.openbell.ai/news/OLLI:1791890345037 2026-10-13T11:19:05.037Z daily 0.9 https://cdn.brandfetch.io/OLLI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ollie’s Bargain Outlet Holdings Board Unanimously Approves New Share Repurchase Authorization For Repurchase Of Additional $500M Of Outstanding Common Stock Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has received unanimous approval from its Board of Directors for a new share repurchase authorization, allowing for the repurchase of an additional $500 million of its outstanding common stock. This brings the total share repurchase capacity to approximately $561 million, including the existing authorization. https://www.openbell.ai/news/TLRY:1791890281618 2026-10-13T11:18:01.618Z daily 0.9 https://cdn.brandfetch.io/TLRY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tilray Brands’ Unit Tilray Medical Secures Key Regulatory Approval For In-House Testing At Portugal Facility Tilray Medical, a division of Tilray Brands, has received regulatory approval from Portugal's INFARMED for its quality control laboratory at its EU-GMP-certified facility in Cantanhede. This approval allows for in-house microbiological and chemical/physical testing, enhancing product release capabilities and positioning the facility as a key hub for pharmaceutical-grade medical cannabis supply in international markets. The move is expected to strengthen Tilray's European production platform amid increasing demand for medical cannabis. https://www.openbell.ai/news/IQV:1791890129980 2026-10-13T11:15:29.980Z daily 0.9 https://cdn.brandfetch.io/IQV/w/400/h/400?c=1idopYfmtR7ZKg8QMud IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studies IQVIA has expanded its partnership with Veeva Systems to include Veeva CTMS, eTMF, Study Startup, and Site Connect as standard applications for its clinical development studies. This follows a previously announced EDC partnership and aims to enhance trial speed and efficiency, improve site centricity, and facilitate better decision-making in clinical research. All Veeva clinical solutions will be accessible through IQVIA for sponsors seeking a complete Veeva technology stack. https://www.openbell.ai/news/BEAM:1791890076999 2026-10-13T11:14:36.999Z daily 0.9 https://cdn.brandfetch.io/BEAM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT Beam Therapeutics Inc. will present initial data from its Phase 1/2 clinical trial of BEAM-301 for glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the ESGCT from October 27-30, 2026. The data indicate clinical proof of concept for the genetic correction of the R83C mutation, showing restoration of endogenous glucose production and dose-dependent improvements in key endpoints. The safety profile of BEAM-301 aligns with that of other lipid-nanoparticle based therapies. https://www.openbell.ai/news/QUIK:1791890022087 2026-10-13T11:13:42.087Z daily 0.9 https://cdn.brandfetch.io/QUIK/w/400/h/400?c=1idopYfmtR7ZKg8QMud QuickLogic Awarded Six-Figure eFPGA Hard IP Design Win For A Programmable System-On-Chip QuickLogic Corporation (NASDAQ: QUIK) has secured a six-figure eFPGA Hard IP design win for a programmable system-on-chip (SoC) aimed at battery management and industrial robotic applications, utilizing 16nm automotive process technology. The contract is expected to generate license revenue over the next six months, with additional royalty revenue anticipated upon production shipments. This design win enhances QuickLogic's presence in the growing robotics and battery management semiconductor markets, driven by the rise of electric vehicles and renewable energy solutions. https://www.openbell.ai/news/NBP:1791890004293 2026-10-13T11:13:24.293Z daily 0.9 https://cdn.brandfetch.io/NBP/w/400/h/400?c=1idopYfmtR7ZKg8QMud NovaBridge’s Visara Plans To Develop HT006.2.2 As VIS-102, Second Clinical-Stage Program, Expanding Its Ophthalmology Portfolio Beyond Retinal Vascular Disease Into Ocular Surface Disease Visara, a subsidiary of NovaBridge Biosciences (NASDAQ: NBP), has secured exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2, which will be branded as VIS-102. This investigational therapy aims to treat neurotrophic keratitis by restoring corneal health and offers a more convenient treatment option. The development of VIS-102 marks Visara's second clinical-stage program, expanding its portfolio into ocular surface disease beyond retinal vascular conditions. https://www.openbell.ai/news/QBTS:1791889876947 2026-10-13T11:11:16.947Z daily 0.9 https://cdn.brandfetch.io/QBTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud D-Wave Quantum Enters Multi-Year Agreement With SkyWater Technology To Continue Specialized Semiconductor Process Development And Manufacturing D-Wave Quantum Inc. has entered a multi-year agreement with SkyWater Technology to continue specialized semiconductor process development and manufacturing, enhancing their long-standing partnership. This collaboration will support D-Wave's quantum technology roadmap and protect its intellectual property. The companies have previously worked together on projects that improved manufacturing efficiency, including a proof-of-technology project that reduced lot delays by up to 30%. D-Wave's Advantage2 processors, developed in conjunction with SkyWater, have demonstrated superior performance in quantum simulations. https://www.openbell.ai/news/LTRX:1791889768136 2026-10-13T11:09:28.136Z daily 0.9 https://cdn.brandfetch.io/LTRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lantronix Unveils Robotics Platform Spotter To Provide Drone And Robot Makers The Onboard Compute, Sensing And Vehicle Control To Run Autonomy Lantronix has introduced its new robotics platform, Spotter, at AUSA 2026, with plans for availability in Q4 2026. Spotter aims to address a gap in the compute market for unmanned systems by providing up to 12.5 TOPS of AI performance on a compact board, designed specifically for drones and mobile robots. It supports various existing platforms and offers a production-ready solution for OEMs, leveraging Lantronix's engineering services and existing trust in defense programs. https://www.openbell.ai/news/GOGO:1791889717371 2026-10-13T11:08:37.371Z daily 0.9 https://cdn.brandfetch.io/GOGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gogo Says Duncan Aviation Places Prepaid Order For 40 Gogo Galileo HDX Systems Gogo (NASDAQ: GOGO) announced a prepaid order from Duncan Aviation for 40 Gogo Galileo HDX systems, representing Gogo's largest single MRO order of the year. This order highlights Duncan Aviation's commitment to providing high-performance connectivity solutions to aircraft owners and operators, driven by anticipated customer demand. https://www.openbell.ai/news/SCNI:1791889550893 2026-10-13T11:05:50.893Z daily 0.9 https://cdn.brandfetch.io/SCNI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Scinai Expands CDMO Business with $5.1M Development and Clinical Manufacturing Agreement openbell Financial News https://www.openbell.ai/news/SKHY:1791889489062 2026-10-13T11:04:49.062Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Paris--France---February-20-2026-The-Sk-.jpg?width=250&height=187 China's Memory Chip Push Sends SK hynix, Samsung Reeling: Is the AI Trade Losing Steam? SK hynix Inc. shares fell over 5% amid increasing competition from China's ChangXin Memory Technologies (CXMT), which has made advancements in chip architecture. The stock dropped more than 10% in Seoul, while Samsung Electronics also saw a decline of 7.4%, both reaching their lowest levels since August. The broader selloff in AI-linked semiconductor stocks has raised concerns about the global supply-demand balance, although experts believe that the immediate threat from Chinese competitors remains limited. https://www.openbell.ai/news/ELBM:1791889477264 2026-10-13T11:04:37.264Z daily 0.9 https://cdn.brandfetch.io/ELBM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Electra Battery Materials Signs Term Sheet With WMC Group For 5-Yr Working-Capital And Commercial Partnership Supporting Canadian Critical Minerals Refinery openbell Financial News https://www.openbell.ai/news/LAZ:1791889440893 2026-10-13T11:04:00.893Z daily 0.9 https://cdn.brandfetch.io/LAZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Goldman Sachs Maintains Sell on Lazard, Lowers Price Target to $32 Goldman Sachs analyst James Yaro has maintained a 'Sell' rating on Lazard (NYSE: LAZ) and has reduced the price target from $36 to $32. This change reflects a more cautious outlook on the company's stock performance. https://www.openbell.ai/news/ENTA:1791889423004 2026-10-13T11:03:43.004Z daily 0.9 https://cdn.brandfetch.io/ENTA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Enanta Pharmaceuticals To Present Data For Zelicapavir, Oral, Once-Daily, N-Protein Inhibitor In Development For Treatment Of Respiratory Syncytial Virus At IDWeek 2026 Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that it will present data for zelicapavir, an oral, once-daily N-protein inhibitor aimed at treating respiratory syncytial virus (RSV), at IDWeek 2026. The event is scheduled for October 21-24, 2026, and will take place virtually as well as at the Walter E. Washington Convention Center in Washington, DC. https://www.openbell.ai/news/ENTX:1791889349574 2026-10-13T11:02:29.574Z daily 0.9 https://cdn.brandfetch.io/ENTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting Entera Bio Ltd. presented post-hoc Phase 2 data at the ASBMR 2026 Annual Meeting, indicating that EB613 shows greater bone mineral density gains in postmenopausal women with osteoporosis compared to those with osteopenia. The findings support the potential benefits of EB613 for women at high risk for fractures, aligning with the study population for Entera's upcoming Phase 3 study. The presentations included a Plenary Poster and a Late-breaking Poster, highlighting the company's advancements in oral peptide development. https://www.openbell.ai/news/FRSX:1791889194650 2026-10-13T10:59:54.650Z daily 0.9 https://cdn.brandfetch.io/FRSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Foresight Enters Non-Binding Term Sheet To Acquire 50.01% Controlling Stake In A Polish Data Center Development Company; Price To Be Decided By Independent Evaluation; Company Expects To Contribute Estimated ~$1M And Additional Shareholder Loans Of Up To $2.5M To Advance The Two Projects Foresight has entered a non-binding term sheet to acquire a 50.01% controlling stake in a Polish data center development company, with the purchase price to be determined by an independent evaluation. The company plans to contribute approximately $1 million and may provide additional shareholder loans of up to $2.5 million to advance two projects in Warsaw and Wroclaw, which have a combined planned capacity of up to 270 MW. The transaction is subject to due diligence, independent valuation, and various approvals. https://www.openbell.ai/news/SNDX:1791889167952 2026-10-13T10:59:27.952Z daily 0.9 https://cdn.brandfetch.io/SNDX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ: SNDX) and maintained a price target of $38 for the stock. https://www.openbell.ai/news/VFC:1791889067514 2026-10-13T10:57:47.514Z daily 0.9 https://cdn.brandfetch.io/VFC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Truist Securities Upgrades VF to Buy, Raises Price Target to $20 Truist Securities has upgraded VF Corporation (NYSE: VFC) from a Hold to a Buy rating. The price target for the stock has been increased from $14 to $20. https://www.openbell.ai/news/ETRA:1791888878104 2026-10-13T10:54:38.104Z daily 0.9 https://cdn.brandfetch.io/ETRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Initiates Coverage On Electra Therapeutics with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt has initiated coverage on Electra Therapeutics (NASDAQ: ETRA) with an Overweight rating. This marks a significant endorsement for the company as it seeks to attract investor interest. https://www.openbell.ai/news/EONR:1791888826681 2026-10-13T10:53:46.681Z daily 0.9 https://cdn.brandfetch.io/EONR/w/400/h/400?c=1idopYfmtR7ZKg8QMud EON Resources Discloses Q4 FY25 Error In Depletion, Depreciation And Amortization Expense; Expects To Reduces FY25 Loss To Shareholders From $10.1M To $7.5M EON Resources Inc. identified an error in its fourth quarter depletion, depreciation, and amortization expense for FY25, overstating it by $3.54 million. This adjustment will reduce the reported loss to shareholders from $10.1 million to approximately $7.5 million. The company plans to file an amended Form 10-K, and the restatement is non-cash, meaning it will not affect cash flows or cash equivalents. https://www.openbell.ai/news/BRSL:1791888595382 2026-10-13T10:49:55.382Z daily 0.9 https://cdn.brandfetch.io/BRSL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brightstar Lottery Enters Five-Year Licensing Agreement With Pan American World Airways To Develop And Distribute Pan Am-Themed Omnichannel Lottery Games Worldwide Brightstar Lottery has entered a five-year licensing agreement with Pan American World Airways to develop and distribute Pan Am-themed omnichannel lottery games globally. The deal encompasses a range of offerings, including instant tickets, draw-based games, and iLottery games, while also utilizing Pan Am's expertise in luxury trip planning to enhance player experiences. This strategic partnership aims to provide unique travel opportunities for lottery players and winners of second chance promotions. https://www.openbell.ai/news/GRO:1791888592574 2026-10-13T10:49:52.574Z daily 0.9 https://cdn.brandfetch.io/GRO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brazil Potash Announces Encouraging Initial Results From Testing Of AI-Powered X-Ray Transmission Sorting Technology, Initiated When First Announced In December 2025 Brazil Potash Corp. announced positive initial results from testing AI-powered X-ray Transmission (XRT) sorting technology, which indicated that approximately 20% of lower-grade material could be screened out before processing. The testwork, conducted with ERCOSPLAN, showed that a sample containing about 13% KCl was upgraded to approximately 27% KCl. The company plans to conduct further tests and economic studies to evaluate the potential implementation of this technology at the Autazes Project to increase production and extend mine life. https://www.openbell.ai/news/BOX:1791888557004 2026-10-13T10:49:17.004Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Box-Headquarters-In-Redwood-City--Califo.jpg?width=250&height=187 Box CEO Aaron Levie Says AI Agent Swarms Could Become Enterprise ‘Core’ as Cybersecurity Emerges as a Massive Token Use Box Inc. CEO Aaron Levie stated that AI agent swarms could become a core component of enterprise workflows, particularly in cybersecurity, where they can identify vulnerabilities in complex systems. He emphasized that these AI agents could handle multiple attack scenarios simultaneously, making them valuable for protecting a wide range of assets. Levie also noted that the demand for enterprise tokens could increase significantly as companies seek to secure their IT systems and data. https://www.openbell.ai/news/MRK:1791888517363 2026-10-13T10:48:37.363Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma Merck (NYSE: MRK) will present first-time results from three pivotal clinical trials at the ESMO Congress 2026 in Madrid from October 23-27, highlighting improvements in recurrence-free survival and distant metastasis-free survival for patients with completely resected stage IIB-IV melanoma. The presentations include data from the Phase 3 INTerpath-001 trial evaluating the mRNA-based therapy intismeran combined with KEYTRUDA, and the TroFuse-005 trial for advanced endometrial cancer. Additionally, Merck will host an Oncology Investor Event on October 26 to discuss its oncology strategy and programs. https://www.openbell.ai/news/BNTX:1791888429823 2026-10-13T10:47:09.823Z daily 0.9 https://cdn.brandfetch.io/BNTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioNTech Reports AHEAD-MERIT Phase 2/3 Clinical Trial Did Not Meet First Dual Primary Endpoint Of Progression-Free Survival For mRNA Cancer Immunotherapy Candidate BNT113 Plus Pembrolizumab Compared With Pembrolizumab Alone BioNTech SE announced that its AHEAD-MERIT Phase 2/3 clinical trial for the mRNA cancer immunotherapy candidate BNT113, in combination with pembrolizumab, did not meet the first dual primary endpoint of progression-free survival compared to pembrolizumab alone. The trial will continue to assess the second primary endpoint of overall survival, which could still yield a positive outcome under the trial's statistical design. This investigational therapy targets HPV16-derived antigens in patients with HPV-positive head and neck squamous cell carcinoma, highlighting BioNTech's focus on mRNA cancer immunotherapies as a key part of its oncology strategy. https://www.openbell.ai/news/TSLA:1791888303828 2026-10-13T10:45:03.828Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/13/Almaty--Kazakhstan---10-17-2024--Maye-Mu.jpg?width=250&height=187 Maye Musk Praises Elon Musk’s ‘Safety First’ Focus After Tesla Owner Says EV Saved Him and Son in Crash Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk emphasized the company's commitment to safety after a Tesla owner credited the vehicle's safety features for saving his and his son's lives in a recent crash. Musk's mother, Maye Musk, praised his 'Safety First' approach, stating that it has been a priority since Tesla's inception. Meanwhile, the National Highway Traffic Safety Administration (NHTSA) has launched a probe into Tesla's Robotaxi network following reports of speeding in school zones, with Tesla required to respond to safety-related questions by October 30. TSLA shares were down 1.07% to $373.99 in pre-market trading. https://www.openbell.ai/news/NHP:1791888281289 2026-10-13T10:44:41.289Z daily 0.9 https://cdn.brandfetch.io/NHP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Initiates Coverage On National Healthcare with Outperform Rating, Announces Price Target of $20 Raymond James analyst David Rodgers has initiated coverage on National Healthcare (NASDAQ: NHP) with an Outperform rating. The firm has set a price target of $20 for the company's stock. https://www.openbell.ai/news/AEP:1791888273761 2026-10-13T10:44:33.761Z daily 0.9 https://cdn.brandfetch.io/AEP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Keybanc Upgrades American Electric Power to Overweight, Announces $133 Price Target Keybanc analyst Sophie Karp has upgraded American Electric Power (NASDAQ: AEP) from Sector Weight to Overweight. The firm has set a price target of $133 for the company's stock. https://www.openbell.ai/news/AHR:1791888190054 2026-10-13T10:43:10.054Z daily 0.9 https://cdn.brandfetch.io/AHR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Initiates Coverage On American Healthcare REIT with Strong Buy Rating, Announces Price Target of $62 Raymond James analyst David Rodgers has initiated coverage on American Healthcare REIT (NYSE: AHR) with a Strong Buy rating. The firm has set a price target of $62 for the company's stock.